BioNexus Gene Lab (BGLC) risk factors, FY2025 10-K

Other

1. 01We are an early commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance
2. 02Our competitiveness and growth depend on our ability to fund our capital expenditures. We cannot assure you that we will be able to fund our capital expenditures at reasonable costs due to adverse macroeconomic conditions, our performance or other external factors
3. 03Our ability to collect its accounts receivable
4. 04Our net losses may continue in the future
5. 05Any additional capital we raise may not be available on satisfactory terms and may adversely affect stockholders’ holdings or rights
6. 06Raising additional capital may lead to dilution of shareholdings by our existing shareholders, restrict our operations, and may further result in fair value loss, adversely affecting our financial results

General Business and Industry Risks

1. 07Global economic conditions could materially adversely impact demand for our products and services
2. 08Our risk management programs, processes, or procedures for identifying and addressing risks in MRNA Scientific’s business may not be adequate or effectively applied, and this may adversely impact its businesses
3. 09We may be adversely impacted by changes in laws and regulations, or in their application42% rewritten
4. 10Business disruptions could seriously harm our future revenue and financial condition and increase its costs and expenses
5. 11Our lack of insurance could expose us to significant costs and business disruption
6. 12Fluctuations in foreign currency exchange rates could have a material adverse effect on our financial results

Risk Related to MRNA Scientific’s Business and Industry

1. 13Exponential growth in biotechnology32% rewritten
2. 14MRNA Scientific’s inability to manage growth could harm its business
3. 15MRNA Scientific’s financial prospects depend substantially upon the successful commercialization of the Company’s services and products in the future, which may fail or experience significant delays
4. 16The marketing, sale and use of MRNA Scientific’s products and services could result in substantial damages arising from products or service liability or professional liability claims, that exceed MRNA Scientific’s resources
5. 17MRNA Scientific may face technology transfer challenges and expenses in adding new tests to its portfolio and in expanding its reach into new geographical areas
6. 18MRNA Scientific’s biomarkers have not undergone clinical trials
7. 19MRNA Scientific currently receives and expects to continue to receive a significant portion of its revenues from its genomic screening products, and if its efforts to further increase the use and adoption of these products fail, its business will be harmed
8. 20MRNA Scientific’s success depends on their ability to improve and enhance its current tests and new test candidates, which is complex and costly, and the results are uncertain
9. 21These and other factors beyond MRNA Scientific’s control could delay its launch of enhanced, improved, or new test and test candidates
10. 22Any system failure or security breach or lapse that results in the release of user data could harm MRNA Scientific’s reputation and brand and, consequently, MRNA Scientific’s business, in addition to exposing us to potential legal liability
11. 23MRNA Scientific’s software is highly complex and may contain undetected errors
12. 24MRNA Scientific’s use of “open source” software could subject its proprietary software to general release, adversely affect its ability to sell its tests and subject the company to possible litigation
13. 25MRNA Scientific may face competition from other biotechnology competitors and its operating results will suffer if MRNA Scientific fail to compete effectively
14. 26In addition, smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. In addition, many universities and private and public research institutes may become active in MRNA Scientific’s target disease areas
15. 27Cyber breaches, loss of data, and other disruptions could compromise sensitive information related to MRNA Scientific’s business or prevent us from accessing critical information and expose us to liability, which could adversely affect MRNA Scientific’s business and its reputation
16. 28MRNA Scientific plans to expand its tests and services to multiple countries exposes us to risks associated with doing business outside of Malaysia. The expansion may not be successful, which could limit MRNA Scientific’s ability to grow its revenue, net income, and profitability

Risk Related to Chemrex’s Business and Industry

1. 29The chemical raw material industry is cyclical and both recessions and prolonged periods of slow economic growth could have an adverse effect on Chemrex’s business54% rewritten
2. 30Chemrex, as a reseller, relies on outside vendors to supply us with raw materials, including fibre reinforced plastics. Chemrex purchases most of its primary raw material, from numerous other sources located throughout Malaysia and internationally
3. 31Disruptions in the supply of chemicals that we distribute or in the operations of our customers could adversely affect our business
4. 32We have oral contracts with suppliers and customers, which are generally terminable upon notice, and the termination of our relationships with suppliers and customers contracts could negatively affect our business
5. 33We may lose customers and suffer damage to our reputation if we are unable to meet customer demand for a particular product
6. 34We may be exposed to product returns and product liability claims and latent defect liability claims

Risks Related to Our Operations

1. 35Our officers and directors may in future have outside business activities. As a result, there may be potential conflicts of interest and negatively impact the amount of time they will be able to dedicate to the company
2. 36We may not be able to attract and retain key senior management members and research and development personnel
3. 37We may be unable to protect the company’s intellectual property adequately
4. 38We may be subject to intellectual property claims, which are extremely costly to defend, could require us to pay significant damages and could limit the company’s ability to use certain technologies in the future
5. 39We may be required to restate our financial statements or make material adjustments due to ongoing investigations into past governance failures at our Chemrex subsidiary
6. 40Our internal controls over financial reporting may remain deficient due to legacy governance gaps and evolving compliance frameworks
7. 41We may pursue collaborations, in-licensing or out-license arrangements, joint ventures, strategic alliances, partnerships or other strategic investments or arrangements, which may fail to produce anticipated benefits and adversely affect the company’s operations
8. 42partners, collaborators, or other parties may own or co-own intellectual property covering our services and products that results from our collaborations with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property

Risks Related to Doing Business in the Southeast Asia Region

1. 43Changes in policies in Malaysia and other Southeast Asian countries could have a significant impact upon the company’s ability to operate profitably in Malaysia and the Southeast Asia region
2. 44Developments in the social, political, regulatory and economic environment in Malaysia may have a material adverse impact on us71% rewritten
3. 45You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in Malaysia against the company or its management based on foreign laws, and the ability of U.S. authorities to bring actions in Malaysia may also be limited
4. 46We are subject to foreign exchange control policies in Malaysia
5. 47Volatility in our share price may subject us to securities litigation
6. 48We may never be able to pay dividends and are unlikely to do so
7. 49Shareholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of securities
8. 50We are a “smaller reporting company,” and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors